These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 26993495

  • 21. Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.
    Tomiyama H, Miwa T, Kan K, Matsuhisa M, Kamiya H, Nanasato M, Kitano T, Sano H, Ohno J, Iida M, Sata M, Yamada H, Maemura K, Tanaka A, Murohara T, Node K.
    Cardiovasc Diabetol; 2016 Nov 03; 15(1):150. PubMed ID: 27809848
    [Abstract] [Full Text] [Related]

  • 22. Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.
    Toth PP.
    Vasc Health Risk Manag; 2015 Nov 03; 11():9-23. PubMed ID: 25565858
    [Abstract] [Full Text] [Related]

  • 23. Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis.
    Loh HH, Yee A, Loh HS, Sukor N, Kamaruddin NA.
    Prim Care Diabetes; 2016 Jun 03; 10(3):210-9. PubMed ID: 26392074
    [Abstract] [Full Text] [Related]

  • 24. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE, Bhosekar V, Kawamori R.
    Vasc Health Risk Manag; 2016 Jun 03; 12():9-12. PubMed ID: 26855580
    [Abstract] [Full Text] [Related]

  • 25. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
    Widlansky ME, Puppala VK, Suboc TM, Malik M, Branum A, Signorelli K, Wang J, Ying R, Tanner MJ, Tyagi S.
    Vasc Med; 2017 Jun 03; 22(3):189-196. PubMed ID: 28145158
    [Abstract] [Full Text] [Related]

  • 26. The effects of linagliptin on endothelial function and global arginine bioavailability ratio in coronary artery disease patients with early diabetes: study protocol for a randomized controlled trial.
    Tripolt NJ, Aberer F, Riedl R, Hutz B, Url J, Dimsity G, Meinitzer A, Stojakovic T, Hödl R, Brodmann M, Hafner F, Sourij H.
    Trials; 2016 Oct 13; 17(1):495. PubMed ID: 27733180
    [Abstract] [Full Text] [Related]

  • 27. Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients.
    Fujiwara T, Yoshida M, Nakamura T, Sakakura K, Wada H, Arao K, Katayama T, Funayama H, Sugawara Y, Mitsuhashi T, Kakei M, Momomura S, Ako J.
    Heart Vessels; 2015 Sep 13; 30(5):696-701. PubMed ID: 24736945
    [Abstract] [Full Text] [Related]

  • 28. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H, Soga F, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI.
    Cardiovasc Diabetol; 2020 Jan 07; 19(1):6. PubMed ID: 31910853
    [Abstract] [Full Text] [Related]

  • 29. DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes.
    Kozlovski P, Bhosekar V, Foley JE.
    Vasc Health Risk Manag; 2017 Jan 07; 13():123-126. PubMed ID: 28408838
    [Abstract] [Full Text] [Related]

  • 30. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
    Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K.
    Cardiovasc Diabetol; 2018 May 22; 17(1):73. PubMed ID: 29788955
    [Abstract] [Full Text] [Related]

  • 31. Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus.
    Barchetta I, Ciccarelli G, Barone E, Cimini FA, Ceccarelli V, Bertoccini L, Sentinelli F, Tramutola A, Del Ben M, Angelico F, Baroni MG, Lenzi A, Cavallo MG.
    Nutr Metab Cardiovasc Dis; 2019 Oct 22; 29(10):1087-1094. PubMed ID: 31431395
    [Abstract] [Full Text] [Related]

  • 32. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S, Shigiyama F, Hisatake S, Mizumura S, Shiraga N, Hori M, Ikeda T, Hirose T, Kumashiro N.
    Cardiovasc Diabetol; 2021 Feb 02; 20(1):32. PubMed ID: 33530982
    [Abstract] [Full Text] [Related]

  • 33. Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus.
    Fan Y, Zhang Y, Li X, Zheng H, Song Y, Zhang N, Shen C, Fan X, Ren F, Shen J, Ren G, Yang J.
    Drug Des Devel Ther; 2015 Feb 02; 9():4679-83. PubMed ID: 26316706
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
    Bonora E, Bryzinski B, Hirshberg B, Cook W.
    Nutr Metab Cardiovasc Dis; 2016 May 02; 26(5):374-9. PubMed ID: 27033025
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.